Related Experiment Video

Updated: Jun 7, 2025

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.6K

Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases

Runfang Pan1, Yuqing He1, Wan Melisandre1

  • 1Department of Anatomy, School of Chinese Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Frontiers in Pharmacology
|November 14, 2024
PubMed
Abstract

Insights

Sodium-glucose transporter 2 inhibitors (SGLT2i) show growing promise in treating cardiovascular diseases (CVD), particularly heart failure. Bibliometric analysis reveals increasing research and key areas like empagliflozin and dapagliflozin applications.

Area of Science:

  • Cardiology
  • Pharmacology
  • Bibliometrics

Background:

  • Cardiovascular diseases (CVD) present a significant global health challenge with increasing prevalence.
  • Sodium-glucose transporter 2 inhibitors (SGLT2i), initially for type 2 diabetes, demonstrate potential in mitigating CVD risk, especially in heart failure (HF) and atherosclerosis (ASCVD).

Purpose of the Study:

  • To conduct a bibliometric analysis of Sodium-glucose transporter 2 inhibitors (SGLT2i) in cardiovascular disease (CVD) research.
  • To identify current research trends, hotspots, and future directions for SGLT2i in CVD treatment.

Main Methods:

  • Bibliometric analysis of 3,476 studies (2,293 articles, 1,183 reviews) sourced from Web of Science.
  • Utilized CiteSpace and VOSviewer to create knowledge maps and analyze publication trends and keywords.

Main Results:

  • A notable increase in publications on SGLT2i for CVD, peaking in 2022.
  • The United States leads in publications and citations, while China shows a growing contribution.
  • Key research terms include empagliflozin, dapagliflozin, diabetes, and heart failure.

Conclusions:

  • Bibliometric analysis confirms a robust and expanding research interest in SGLT2i for CVD.
  • This review offers valuable insights into research progress, hotspots, and future prospects for SGLT2i in cardiovascular medicine.
Keywords:
CitespaceVOSviewerbibliometric studycardiovascular diseasesodium-glucose transporter 2 inhibitor

More Related Videos

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

2.7K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

527

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.5K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
159
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
172
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
300
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
141